| | More

PHA Proof-of-Concept Research Grants

PHA

You must have received an email from Alyssa Chase (achase@thoracic.org) inviting you to submit a full application in order for your proposal to be accepted.

The grant program is explained below, along with timeline for the review process, eligibility requirements, and application instructions.

Timeline for 2013 PHA Proof-of-Concept Grants
(Funding to begin October 31, 2013)

May 10, 2013 Deadline for submission of letters of intent
June 7, 2013 Review of the LOI’s
Mid-Late June Applicants will receive official notification on their LOI’s
July 19, 2013 Submission deadline for full grant applications
September 29-30, 2013 Review of grant applications
Early-Mid October Award notifications sent to applicants and institutions

Two PHA Proof-of-Concept grants are available:

  • The Matthew and Michael Wojciechowski Pulmonary Hypertension Proof-of-Concept Grant (1)
  • The Pulmonary Hypertension Association Proof-of-Concept Grant (3)

PHA has contracted with the American Thoracic Society for administrative services for this program.

The target audience for the research grants will be investigators interested in research in pulmonary hypertension (PH).

The purpose of the program is to support new research projects that are in the early exploratory and developmental stages and have the potential to lead to advances in the scientific understanding of PH. The proposed project should result in preliminary data that will enable the investigator to apply for support for a larger, hypotheses-driven research project.

Applicants may request up to $25,000 in direct costs for one year to be used for salaries and/or supplies to conduct this research. Additionally, the grant will provide $2,500 in indirect (facilities and administrative) costs. Both US and non-US based investigators are encouraged to apply.

Eligibility and Guidelines

Please read the eligibility information below before you start your application. If you have any questions, please contact Alyssa Chase, Senior Manager of the ATS Foundation Research Program, at achase@thoracic.org.

We encourage U.S. and non-U.S. based investigators to apply.

Individuals must submit a letter of intent.  After the letter of intent is reviewed, the ATS will notify applicants regarding whether their eligibility to submit a full application.

Applicants must have completed their primary research training (PhD or sub-specialty fellowship training) by July 1, 2013 and have a firm commitment from their home institution for a faculty position.

Investigators who hold active career development grants (such as K award from the NIH) are eligible to receive PHA research funding, but the PHA project should differ scientifically from the already funded award.

Applicants shall not be over 12 years beyond their doctoral degree or equivalent (i.e., MD, PhD, DVM), and may not be a PI on an NIH RO1 or VA Merit award.

At this time, the following individuals are not eligible to apply for a Proof-of-Concept grant:

  • Current awardees of an ATS/PHA Research grant or Proof-of-Concept grant
  • Individuals who have received 2 PHA grants

Successful applicants are usually early career investigators who are within 5 years of completion of their specialty training and within 10 years of their terminal degree. These candidates do not hold independent federal grants (e.g., NIH RO1, DVA Merit Review, DOD grant) or equivalent, and are not project leaders in multi-investigator NIH projects (e.g., PPG).

Review Process

The ATS Scientific Advisory Committee (SAC) will review the applications in conjunction with the Pulmonary Hypertension Association. The membership of the SAC is listed on the ATS Website. Additional ad hoc reviewers will be invited to participate, as needed. Funding decisions will be made on the basis of conceptual framework, the level of innovation, potential to advance scientific knowledge and understanding, the potential to stimulate scientific advances, and responsiveness to the purpose of the specific grant program.

Application Instructions

Click here for the applications.
You must use the same login credentials that you used to submit the letter of intent.

KEY PERSONNEL

Please a) list the key personnel on your project b) list each of their roles on the project (mentor, consultant, research technician, etc.) c) approximate the total percentage of total effort that the person will contribute to the project.

SYNOPSIS

USING TERMS THAT CAN BE UNDERSTOOD BY A NON-SCIENTIFIC AUDIENCE, please briefly describe what you are investigating, the techniques you will use to support your hypothesis, and how your project will contribute to scientific understanding of your disease of interest.

Note that this General Audience Summary will become public information; therefore, do not include proprietary/confidential information.

PATIENT SUMMARY

Please explain how your research may lead to improved patient outcomes.  A patient advocate may help review and vote on your application.

SUMMARY FOR SAC REVIEWERS

Please provide a technical abstract of your proposal, keeping your response to 5000 characters or less.

FUTURE PLANS

Where would you take this research after funding ends, and how will this support contribute to your research career development?

LAB RESOURCES AND EQUIPMENT

List the resources that you have available to you that will be needed to complete your project.  Describe these resources, and explain how each will contribute to the successful completion of your project.  Please note that the limit for this section is two pages.

This document should be divided into seven sections:

  • Laboratory
  • Clinical
  • Animal
  • Computer
  • Office
  • Major Equipment
  • Other

RESEARCH PLANS (10 page limit)

PLEASE CHECK: The Research Plan (Sections A-D) must be no longer than 10 pages including pictures with margins at .75 (right and left), .50 (top and bottom), using Arial size 11 font with no less than single-line spacing.

The Research Plan should include sufficient information needed for evaluation of the project. The format for preparing this section is provided below. Be specific and informative, and avoid redundancies.

A. STATEMENT OF PROBLEM AND SPECIFIC AIMS

What do you intend to do?

State the problem concisely and describe the specific aims of the research proposal. What is the hypothesis you will test? What is the experimental paradigm?

B. BACKGROUND AND SIGNIFICANCE

Why is the work important?

Briefly provide the scientific background leading to the present application. Critically evaluate existing knowledge and identify the scientific gaps that the project is intended to fill. If the aims of the proposal are accomplished, how will this affect the scientific field? Where will these studies lead in developing a larger research program?

C. WORK ACCOMPLISHED AND PRELIMINARY STUDIES

What has already been done?

Provide an account of the principal investigator’s preliminary studies pertinent to this application. Preliminary data often aid the reviewers in assessing the likelihood of the success of the proposed project. List any publications, manuscripts accepted for publication, patents, or other printed materials that have resulted from preliminary studies.

D. RESEARCH DESIGN AND METHODS

How are you going to do the work?

Describe the research design and methods that you will use in the proposed studies. Organize this section by the specific aims of the research proposal. Include how the data will be collected, and analyzed, and describe potential problems or limitations. Published or commonly used methods do not need to be described in detail. This section must be written so that reviewers can evaluate the scientific questions, the experimental design, and the likelihood that the experiments will produce interpretable results. Include a tentative timetable showing how you will prioritize the work. Clearly identify collaborations with other investigators at the same or other institutions.

LITERATURE CITED

  • No page limit
  • List citations by number in the order in which they appear in the text.
  • Use the following format shown below (“New England Journal of Medicine” style in EndNote and “Annals of Internal Medicine” in Reference Manager).

1. Kajikawa O, Frevert CW, Lin SM, Goodman RB, Mongovin SM, Wong V, Ballman K, Daubeuf B, Elson G, Martin TR. Gene expression of toll-like receptor-2, toll-like receptor-4 and MD2 is differentially regulated in rabbits with Escherichia coli pneumonia. Gene 2005;3:193-202.

2. Altemeier WA, Matute-Bello G, Frevert CW, Kawata Y, Kajikawa O, Martin TR, Glenny RW. Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin. Am J Physiol Lung Cell Mol Physiol 2004;164:1949-1958.

LETTERS OF RECOMMENDATIONS

You are responsible for providing and uploading two (2) reference letters (letters of support). These must be uploaded before you can submit your application. Letters sent directly to the ATS office will NOT be accepted.  Letters of support are usually just that - letters from someone not involved in the project but who can emphasize its importance. Similarly, institutional leaders (e.g., division director, chair, dean) can write letters to highlight their commitment for the candidate.  A mentor could also be included here.  You need to determine the best people to write these letters of support considering that they are included to enhance your application.

Please place all letters of support into a SINGLE ZIP file and upload this file to your application.

LETTER(S) FROM COLLABORATOR(S)

You may also submit letter(s) from collaborator(s) or donor(s) who are providing expertise or reagents needed to accomplish the work. You may submit as many of these letters as you feel are necessary.  Please place all letters from collaborators into a SINGLE ZIP filed and upload this file to your application.

CERTIFICATION OF FACULTY EMPLOYMENT

Click here to complete the signature form. 

BIOSKETCHES

Please note that you MUST observe the limits indicated in the biosketch template (For example, publications must end on page 2). Applications with biosketches that do not meet the requirements will be un-submitted.  Click here to download the biosketch templates.

DISCLOSURE OF CONFLICT OF INTERESTS

Many individuals have competing interests that may cause conflicts of interest. Disclosure and review of a potential "conflict of interest" (COI) that might affect an ATS research award doesn't imply that an "outside interest", or a person with such a relationship or interest, is wrong or inappropriate. Nor does it imply criticism of the character or actions of the individual, or of any commercial or non-commercial entities with which an individual may be involved. Rather, ATS COI policies and procedures exist to assure the public of appropriate levels of transparency of the outside interests of participants in official ATS activities, and that official ATS activities are managed in a manner that maintains scientific rigor and independence.

  • Disclosure of a real or potential COI will not automatically invalidate an application.

All personal financial relationships with commercial entities (such as pharmaceutical companies and medical device manufacturers), and/or with non-commercial, non-governmental funders (such as private foundations), that are relevant to the application’s subject matter must be disclosed. Such involvement with relevant commercial entities (companies) includes employment or ownership; consultancy(ies); Board or advisory committee service; service on speakers' bureaus or other acceptance of lecture fees directly paid by the company; expert testimony on behalf of the company; research grants; patents received or pending; royalties; and stock ownership or options (excluding mutual funds unless a sector fund concentrated in an industry or industries relevant to the activity).

The ATS "Policy on Tobacco Relationships" requires that individuals with a current tobacco industry relationship not hold certain ATS roles, including that of research awardee. (Note: if the relationship is limited to personal holdings of tobacco stocks or options, divestiture of such holdings. See the policy for details.)

PLEASE RESPOND in the corresponding answer spaces on the online application.

COI 1A: Have you within the past 12 months had a financial interest in a commercial entity (i.e., a “commercial interest”) that could be considered broadly relevant to the subject matter of this proposal, or do you expect to have one during the duration of the grant award period?

COI 1B: If yes, please provide the company name(s) and the type of relationship:

COI 2A: Have you within the past 12 months received financial support from a non-commercial, non-governmental source (such as a private foundation or other non-profit source) that could be perceived as a real or potential conflict of interest relevant to the subject matter of this proposal, and/or do you expect to receive such before the end of the grant award period?

COI 2B: If yes, please provide the organization name(s) and the type of relationship:

COI 3A: Have you within the past 12 months had any non-financial affiliation or interest (i.e., a personal, professional or other affiliation or interest) that might be perceived to be a real or potential conflict of interest relevant to the subject matter of this proposal, and/or do you expect to receive such before the end of the grant award period?

COI 3B: If yes, please provide the company or organization name(s) and the type of relationship:

COI 4A: Have you within the past 12 months had a professional relationship with a tobacco entity or expect to have one before the end of the grant award period?

COI 4B: If yes, please provide the company or organization name(s) and the type of relationship:

BUDGET FORM

Click here to complete the budget form.

SIGNATURE PAGE

After you complete all of the proposal sections, you must print the signature page available here, sign it and have your financial administrator sign it. Then, upload the signed page back onto the application as an attachment. Please only upload one signed page. Please do NOT mail the signature page to the ATS office.